monocytesmacrophag
import
contributor
cancerassoci
inflamm
heterogen
macrophag
discuss
regard
differ
respons
variou
microenvironment
stimuli
macrophag
classifi
two
distinct
subtyp
classic
activ
macrophag
stimul
microbi
product
altern
activ
macrophag
stimul
sever
studi
shown
macrophag
infiltr
tumor
microenviron
contribut
cancer
progress
associ
tumor
progress
angiogenesi
metastasi
immunosuppress
macrophag
phenotyp
refer
tumorassoci
macrophag
tam
macrophag
posit
correl
histolog
gradient
malign
human
ovarian
thu
use
marker
activ
tam
human
sampl
furthermor
malign
lymphoma
glioma
kidney
cancer
higher
express
tam
associ
wors
clinic
prognosi
howev
correl
exist
clinic
prognosi
number
also
known
class
scaveng
receptor
sra
shown
particip
pathogenesi
atherosclerosi
pattern
recognit
pathogen
hemoglobin
scaveng
receptor
exclus
express
monocytemacrophag
system
furthermor
recent
data
indic
solubl
may
valuabl
diagnost
paramet
monitor
macrophag
activ
inflammatori
immun
toler
tumor
microenviron
close
involv
tumor
progress
caus
tcell
regul
via
inhibitori
signal
immun
suppress
cytokin
immun
checkpoint
molecul
program
ligand
transform
growth
prostaglandin
wide
express
leukocyt
tumor
cell
recent
studi
demonstr
express
tam
almost
malign
lymphoma
includ
adult
cell
leukemialymphoma
follicular
lymphoma
diffus
larg
bcell
present
studi
investig
local
cell
oral
squamou
cell
carcinoma
oscc
also
examin
level
immun
suppress
molecul
produc
tam
subset
tam
associ
clinic
outcom
studi
design
method
approv
institut
review
board
center
clinic
translat
research
kyushu
univers
hospit
irb
serial
number
method
carri
accord
approv
guidelin
patient
rel
gave
inform
consent
within
written
treatment
contract
admiss
therefor
prior
inclus
studi
enrol
patient
primari
oscc
treat
depart
oral
maxillofaci
surgeri
kyushu
univers
hospit
averag
age
patient
year
rang
twentyseven
patient
male
nineteen
femal
follow
initi
biopsi
specimen
fix
buffer
formalin
solut
embed
paraffin
block
paraffinembed
specimen
process
thick
section
stain
hematoxylin
eosin
examin
experienc
oral
pathologist
confirm
diagnosi
histolog
grade
tumor
stage
classifi
accord
tnm
classif
intern
union
cancer
tumor
histolog
grade
defin
accord
classif
mode
tumor
invas
determin
h
e
stain
specimen
accord
yamamotokohama
criteria
follow
grade
welldefin
borderlin
grade
cord
lessmark
borderlin
grade
group
cell
distinct
borderlin
grade
diffus
invas
c
cordlik
type
widespread
type
patient
tumor
characterist
shown
tabl
deparaffinizationhydr
section
section
wash
three
time
tbst
min
slide
boil
mm
sodium
citrat
buffer
ph
maintain
min
slide
cool
bench
top
min
wash
tbst
three
time
min
section
incub
min
wash
tbst
three
time
min
section
block
block
solut
min
room
temperatur
follow
incub
primari
antibodi
overnight
use
mous
clone
novocastra
newcastl
uk
dilut
mous
clone
transgen
kumamoto
japan
dilut
rabbit
clone
abcam
cambridg
uk
dilut
rabbit
clone
abcam
dilut
rabbit
cell
signal
technolog
usa
dilut
goat
clone
santa
cruz
heidelberg
germani
dilut
antibodi
remov
dab
peroxidas
stain
dab
nacalai
tesqu
japan
ad
section
perform
counterstain
hematoxylin
wash
section
two
time
min
dehydr
mount
section
coverslip
first
incub
section
block
buffer
min
incub
section
primari
antibodi
list
appli
antibodi
respect
group
incub
h
room
temperatur
rins
sampl
three
time
tbst
min
incub
sampl
fluorochromeconjug
secondari
antibodi
alexa
thermo
fisher
scientif
waltham
usa
dilut
antibodi
dilut
buffer
h
room
temperatur
dark
rins
sampl
tbst
coverslip
slide
dapi
vectashield
vector
laboratori
usa
doubl
stain
host
anim
label
fitc
fluorescein
label
dojindo
laboratori
kumamoto
japan
number
posit
cell
immunohistochem
stain
count
section
five
independ
highpow
microscop
field
cancer
nest
immunohistochemistri
number
cell
doubl
immunofluoresc
stain
count
way
pbmc
cellsml
oscc
patient
cultur
pb
stimul
pma
ngml
phorbol
wako
tokyo
japan
ionomycin
ionomycin
calcium
wako
h
macrophag
isol
cultur
pbmc
posit
select
magnet
bead
pe
fitc
microbead
miltenyi
biotec
inc
auburn
ca
accord
manufactur
manual
cell
purifi
pbmc
without
cultur
neg
select
magnet
bead
microbead
miltenyi
biotec
inc
cell
cellsml
preincub
day
complet
cosmedium
medium
supplement
autoserum
preincub
h
pb
addit
pma
ionomycin
activ
cell
cellsml
cocultur
tam
cellsml
day
lymphocyt
preserv
takara
bio
otsu
japan
autoserum
cell
examin
microscop
harvest
flow
cytometr
analysi
express
surfac
marker
case
cell
cultur
carri
glass
slide
observ
confoc
microscopi
harvest
cell
wash
pb
supplement
bsa
wash
cell
incub
room
temperatur
min
pe
antihuman
antibodi
clone
biolegend
san
diego
ca
usa
fitc
antihuman
antibodi
clone
milteni
biotec
bergisch
gladbach
germani
apc
antihuman
clone
biolegend
antihuman
clone
biolegend
pe
mous
biolegend
fitc
rea
control
antibodi
igg
milteni
biotec
apc
mous
biolegend
rat
biolegend
apc
mous
biokegend
use
neg
control
antibodi
cell
tam
cocultur
analyz
use
gate
cell
respect
apoptosi
cell
follow
cultur
tam
measur
stain
biolegend
activ
cell
follow
cultur
tam
measur
stain
apc
antihuman
antibodi
clone
biolegend
statist
analys
perform
jmp
softwar
version
sa
institut
nc
usa
u
test
wilcoxon
test
spearman
rank
correl
coeffici
use
assess
signific
differ
group
progressionfre
surviv
overal
surviv
estim
method
curv
comparison
calcul
use
logrank
test
analys
p
valu
consid
statist
signific
first
perform
immunohistochem
stain
evalu
distribut
tam
activ
immun
cell
marker
oscc
tissu
express
detect
tumor
stroma
around
tumor
strongli
detect
inaround
tumor
express
diffus
detect
inaround
tumor
fig
number
cell
correl
cell
fig
moreov
doubl
immunofluoresc
analysi
found
cell
frequent
detect
around
tumor
fig
show
correl
number
cell
r
p
fig
cell
r
p
supp
fig
clarifi
whether
tam
express
immunosuppress
molecul
doubl
immunofluoresc
stain
tam
marker
perform
shown
fig
cell
red
coloc
cell
green
moreov
number
cell
posit
correl
cell
fig
result
suggest
tam
might
suppress
immun
respons
oscc
increas
product
express
cell
next
compar
express
level
molecul
produc
tam
subset
cell
pbmc
oscc
patient
describ
materi
method
shown
fig
supp
fig
found
cell
express
higher
level
number
cell
surfac
comparison
indic
differ
express
immunosuppress
molecul
among
tam
subset
quantit
confirm
immun
suppress
induc
effect
tam
perform
flow
cytometr
analysi
purifi
cell
cocultur
purifi
cell
describ
materi
method
fig
number
purifi
cell
small
measur
appropri
cell
count
flow
cytometri
dot
plot
allow
us
distinguish
dead
cell
viabl
cell
tam
abil
tam
caus
apoptosi
cell
substanti
measur
cell
follow
cocultur
purifi
cell
number
dead
cell
cocultur
significantli
higher
cocultur
cell
without
tam
fig
hand
abil
tam
inhibit
activ
cell
substanti
measur
cell
follow
cocultur
purifi
cell
number
activ
cell
cocultur
significantli
lower
cocultur
cell
without
tam
fig
next
examin
associ
tam
clinicopatholog
factor
oscc
patient
tam
count
follow
three
method
cell
detect
singl
stain
cell
detect
singl
stain
cell
detect
doubl
stain
shown
tabl
number
cell
show
signific
differ
among
clinicopatholog
factor
number
cell
posit
correl
clinic
classif
mode
invas
preval
distant
metastasi
interestingli
oscc
patient
cervic
nodal
metastasi
show
signific
increas
number
cell
hand
number
cell
neg
correl
clinic
stage
clinic
classif
preval
distant
metastasi
evalu
correl
tam
clinic
outcom
oscc
patient
surviv
rate
calcul
kaplanmei
method
oscc
patient
divid
two
group
accord
mean
number
tam
cell
low
high
express
group
progressionfre
surviv
curv
patient
high
express
group
significantli
unfavor
outcom
low
express
group
signific
differ
among
group
cell
diseasespecif
surviv
curv
patient
signific
differ
among
group
cell
fig
univari
analysi
reveal
progressionfre
surviv
associ
advanc
age
yk
criteria
number
cell
tabl
multivari
analysi
identifi
number
cell
margin
signific
prognost
factor
progressionfre
surviv
hazard
ratio
p
tabl
result
suggest
cell
play
critic
role
suppress
tumor
immun
involv
invas
metastasi
oscc
mechnikov
et
al
first
describ
macrophag
profession
phagocyt
play
key
role
inflamm
natur
cellular
mani
research
thought
activ
macrophag
import
effector
cell
cytotox
kill
tumor
macrophag
classifi
two
major
subset
classic
activ
macrophag
stimul
respons
altern
activ
macrophag
stimul
macrophag
secret
proinflammatori
cytokin
contribut
microbicid
tumoricid
immun
wherea
macrophag
scaveng
debri
contribut
angiogenesi
suppress
adapt
immun
wound
heal
fibrosi
produc
pollard
et
report
macrophag
infiltr
cancer
tissu
polar
phenotyp
involv
develop
tumor
microenviron
induc
angiogenesi
immun
suppress
recent
studi
refer
macrophag
tam
express
specif
marker
member
scaveng
receptor
cysteinerich
famili
class
b
express
subpopul
matur
tissu
best
character
function
essenti
homeostat
one
relat
bind
hemoglobin
haptoglobin
complex
furthermor
macrophag
play
role
resolut
inflamm
found
high
number
inflam
found
strong
infiltr
cell
cell
lesion
nonspecif
ulcer
supp
fig
komohara
et
al
indic
antigen
might
better
marker
antiinflammatori
phenotyp
clear
cell
renal
cell
carcinoma
tissu
compar
prototyp
member
famili
structur
divers
transmembran
receptor
collect
term
scaveng
preferenti
express
dendrit
cell
macrophag
function
pattern
recognit
receptor
capabl
bind
broad
rang
ligand
includ
chemic
modifi
alter
molecul
bacteri
surfac
compon
apoptot
cell
play
role
lipid
metabol
atherogenesi
metabol
sever
studi
shown
defici
result
impair
protect
pathogen
partial
attribut
increas
suscept
anim
overproduct
proinflammatori
cytokin
endotox
emerg
evid
also
implic
suppressor
inflammatori
furthermor
esophag
squamou
cell
carcinoma
demonstr
better
marker
tam
popul
associ
tumor
progress
compar
thu
yet
consensu
regard
two
marker
suitabl
tam
present
studi
examin
express
immunosuppress
tam
oscc
use
clear
differ
local
cell
oscc
section
interestingli
doubl
immunofluoresc
stain
data
reveal
mainli
infiltr
around
tumor
express
higher
level
compar
tam
subset
moreov
posit
correl
number
lead
phosphoryl
signal
induc
previous
report
express
local
nucleu
cancer
cell
scatter
wide
cancer
nest
patient
oscc
advanc
clinic
addit
tam
also
found
activ
function
cell
regul
apoptosi
find
indic
tam
might
play
import
role
immun
suppress
tumor
progress
via
signal
recent
ligand
identifi
second
ligand
constitut
express
variou
immun
cell
includ
cell
b
cell
macrophag
dc
tumor
cell
hand
express
limit
macrophag
malign
tumor
tam
suppress
antitumor
immun
respons
overexpress
therefor
examin
requir
elucid
express
tam
subset
oscc
next
examin
associ
tam
prognosi
oscc
patient
number
tam
oscc
posit
correl
clinic
classif
distant
metastasi
moreov
number
tam
also
significantli
associ
progressionfre
surviv
curv
howev
associ
express
tam
marker
clinic
prognosi
cancer
patient
remain
controversi
hirayama
et
report
high
number
tam
lung
scc
significantli
correl
advanc
clinicopatholog
paramet
poor
prognosi
anoth
studi
show
signific
differ
clinicopatholog
factor
clinic
prognosi
high
low
express
group
tam
result
consist
result
present
studi
contrari
glioma
tam
posit
correl
histolog
contradictori
conclus
may
due
differ
tumor
type
methodolog
conclus
confirm
tam
promot
tcell
apoptosi
immunosuppress
via
predict
unfavor
prognosi
oscc
patient
current
examin
tam
subset
contribut
tumor
prolifer
angiogenesi
oscc
thorough
understand
role
tam
subset
could
lead
develop
novel
pharmacolog
strategi
aim
disrupt
tam
product
inhibit
progress
andor
metastasi
oscc
